Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

In January 2014, the Innovative Pharmaceutical Association of South Africa (IPASA) was accused of planning and funding an advocacy campaign on behalf of its member companies. The campaign allegedly sought to oppose South Africa’s efforts to introduce intellectual property law reforms that would allow for patents belonging to IPASA’s member companies to be limited, and for cheaper generic versions to be produced.

In a leaked email, Merck and other members of IPASA discussed the strategy.

Media items on the IPASA campaign:

 

Business & Human Rights Resource Centre invited IPASA and its member companies to respond:

Members companies' responses & non-responses:

  • Abbott [We have invited Abbott to respond and will indicate here whether it responds]
  • Abbvie [We have invited Abbvie to respond and will indicate here whether it responds]
  • Alcon (part of Novartis) Novartis responded [PDF] on behalf of itself and Alcon
  • Allergan did not respond
  • Amgen [We have invited Amgen to respond and will indicate here whether it responds]
  • AstraZeneca response [PDF]
  • Baxter response [PDF]
  • Bayer response [PDF]
  • Boehringer-Ingelheim response [PDF]
  • Bristol-Myers Squibb referred us to IPASA
  • Covidien [We have invited Covidien to respond and will indicate here whether it responds]
  • Eli Lilly [We have invited Eli Lilly to respond and will indicate here whether it responds]
  • Ferring [We have invited Ferring to respond and will indicate here whether it responds]
  • Galderma response [PDF]
  • GE Health reffered us to IPASA
  • Johnson & Johnson response [PDF]
  • Merck (MSD) response [PDF]
  • Novartis response [PDF]
  • Novo Nordisk response [PDF] indicates it resigned from IPASA following campaign proposal:
  • Norgine [We have invited Norgine to respond and will indicate here whether it responds]
  • Pfizer referred us to IPASA
  • Roche response [PDF] indicates it resigned from IPASA following campaign proposal
  • Sanofi-Aventis [We have invited Sanofi-Aventis to respond and will indicate here whether it responds]
  • Servier [We have invited Servier to respond and will indicate here whether it responds]
  • Takeda referred us to IPASA

 

Novo Nordisk and Roche resigned from IPASA:

Roche resigned from IPASA end of January 2014. The campaign proposed by PAE to IPASA is neither in the interest of Roche, nor of our industry in South Africa, and undermined the good relationship we have established with the South African authorities.

 

We believe that access to quality healthcare is a shared responsibility, requiring all stakeholders to work together, which requires a collaborative and inclusive approach based on mutual trust.   

Get RSS feed of these results

Related stories and components

Company response
19 March 2014

Response by Eli Lilly: re allegations of opposing patent reforms on access to medicines in So. Africa

Read full response

Company non-response
10 March 2014

Abbott Laboratories did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Read more

Company non-response
10 March 2014

AbbVie did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Read more

Company non-response
10 March 2014

Amgen did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Read more

Company non-response
10 March 2014

Ferring Pharmaceuticals did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Read more

Company response
10 March 2014

Response by Norgine Pharmaceuticals: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Read full response

Company non-response
10 March 2014

Servier did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Read more

Company non-response
9 March 2014

Sanofi did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Read more

Company response
23 February 2014

Response by Covidien: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Read full response

Company response
19 February 2014

Response by AstraZeneca: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Read full response